Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4657102 | 0.93 | RAB9A (0.52) | RAB9ANPC1CNR1CNR2MEN1 | |
| SCHEMBL13979620 | 0.87 | TSHR (0.46) | RAB9AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4657708 | 0.87 | RAB9A (0.52) | RAB9ANPC1CNR1CNR2MEN1 | |
| SCHEMBL4656953 | 0.85 | RAB9A (0.55) | RAB9ANPC1CNR1CNR2KMT2A | |
| SCHEMBL4658025 | 0.82 | ALDH1A1 (0.46) | RAB9ANPC1CNR1CNR2MEN1 | |
| SCHEMBL4657218 | 0.81 | MAPT (0.54) | RAB9ANPC1CNR1CNR2MEN1 | |
| SCHEMBL949870 | 0.81 | NR1H4 (0.45) | RAB9ANPC1CNR1CNR2MEN1 | |
| SCHEMBL14544237 | 0.81 | RAB9A (0.51) | RAB9ANPC1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL4657196 | 0.80 | RAB9A (0.54) | RAB9ANPC1CNR1CNR2MEN1 | |
| SCHEMBL4657640 | 0.79 | KMT2A (0.53) | RAB9ANPC1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391199-B1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2008-12-10 | — | — | EP | claimed |
| US-7179817-B2 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | claimed |
| US-20040224941-A1 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-11 | — | — | US | claimed |
| EP-1391199-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | claimed |
| EP-1391199-B1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20070088027-A1 | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-04-19 | — | — | US | disclosed |
| US-7179817-B2 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040224941-A1 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
| EP-1391199-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088027-A1 | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | EDF1, FFAR1, EDNRA | RAB9A 4149/4885NPC1 2652/4885ADRA2B 1274/4885 |
| US-20040224941-A1 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | EDF1, FFAR1, VCAM1 | RAB9A 4064/4885NPC1 1756/4885ADRA2B 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.